GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GB Sciences Inc (OTCPK:GBLX) » Definitions » LT-Debt-to-Total-Asset

GB Sciences (GB Sciences) LT-Debt-to-Total-Asset : 0.51 (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is GB Sciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. GB Sciences's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.51.

GB Sciences's long-term debt to total assets ratio increased from Dec. 2022 (0.00) to Dec. 2023 (0.51). It may suggest that GB Sciences is progressively becoming more dependent on debt to grow their business.


GB Sciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for GB Sciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GB Sciences LT-Debt-to-Total-Asset Chart

GB Sciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.25 0.03 0.16 -

GB Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.11 0.32 0.51

GB Sciences LT-Debt-to-Total-Asset Calculation

GB Sciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )/Total Assets (A: Mar. 2023 )
=0/0.352
=

GB Sciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0.075/0.147
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GB Sciences  (OTCPK:GBLX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


GB Sciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of GB Sciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


GB Sciences (GB Sciences) Business Description

Traded in Other Exchanges
Address
9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148
GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments.
Executives
John C Poss director, officer: Chief Executive Officer
Craig Ellins director, 10 percent owner, officer: CEO 3035 EAST PATRICK LANE, SUITE 9, LAS VEGAS NV 89120
Lazarus Management Co Llc 10 percent owner 260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Israel Opportunities Fund Lllp 10 percent owner C/O IBEX GP LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Investment Partners Lllp 10 percent owner C/O IBEX INVESTORS LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Justin B Borus 10 percent owner 260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206

GB Sciences (GB Sciences) Headlines

From GuruFocus

Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility

By GuruFocusNews GuruFocusNews 01-11-2022

Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives

By GuruFocusNews GuruFocusNews 12-06-2021